Previous 10 | Next 10 |
2023-08-09 12:12:37 ET Zentalis Pharmaceuticals press release ( NASDAQ: ZNTL ): Q2 GAAP EPS of -$1.85. Cash and Marketable Securities Position: As of June 30, 2023, Zentalis had cash, cash equivalents and marketable securities of $553.0 million. For further details s...
Azenosertib monotherapy achieved an ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients who received intermittent dosing Identified azenosertib monotherapy RP2D, which more than doubles exposure levels, maintains safety and improves tolerability wit...
NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, tod...
2023-06-21 10:07:44 ET Gainers: Ocean Biomedical ( OCEA ) +43% . PetVivo Holdings ( PETV ) +23% . Patterson Companies ( PDCO ) +14% . Zentalis Pharmaceuticals ( ZNTL ) +5% . RenovoRx ( RNXT ) +4% . Losers: uniQure ( ...
2023-06-17 10:30:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...
2023-06-15 10:06:53 ET Gainers: Aldeyra Therapeutics ( ALDX ) +11% . Bioventus ( BVS ) +11% . IO Biotech ( IOBT ) +11% . Verastem ( VSTM ) +10% . Zentalis Pharmaceuticals ( ZNTL ) +9% . Losers: Mersana Therapeutics ( MRSN...
2023-06-15 06:05:27 ET Zentalis Pharmaceuticals ( NASDAQ: ZNTL ) prices a common stock offering of 11.03M at $22.66 per share, for total gross proceeds of ~$250M. The offering is expected to close on June 20, 2023. Net proceeds from the offering will be used to f...
2023-06-07 07:00:00 ET Summary High-yield dividend stocks are appealing, but they carry high amounts of risk. I demonstrate multiple examples. We present our new strategy to achieve high yields and 76 trades to snipe at market open. Written by Sam Kovacs Intr...
ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D more than doubles exposure levels, maintains safety and improves tolerability with no tre...
2023-06-02 14:34:00 ET Shares of Zentalis Pharmaceuticals (NASDAQ: ZNTL) were down 13.5% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence . The healthcare company closed last week at $30.05 then fell as low as $25.17 on Th...
News, Short Squeeze, Breakout and More Instantly...
Zentalis Pharmaceuticals Inc. Company Name:
ZNTL Stock Symbol:
NASDAQ Market:
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is one of today's top gainers. The company's shares have moved 30.16% on the day to $5.39. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatme...
2024-06-20 08:30:04 ET UBS analyst issues NEUTRAL recommendation for ZNTL on June 20, 2024 06:35AM ET. ZNTL was trading at $4.14 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 4 - Hold recommend...
A look at the top 10 most actives in the United States Reliance Global Group Inc. (RELI) rose 76.2% to $0.3911 on volume of 383,719,808 shares NLS Pharmaceutics Ltd. (NLSP) rose 82.1% to $0.2701 on volume of 302,290,803 shares NVIDIA Corporation (NVDA) rose 3.5% to $135.58 on volume of 28...